Enterome to Participate at the Microbiome Drug Development Summit 2016 and the Festival of Genomics in Boston, USA
PARIS and BOSTON, June 29, 2016 /PRNewswire/ --
ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that Pierre Bélichard, Chief Executive Officer and Rodolphe Clerval, Chief Business Officer will participate at the following conferences:
- The Microbiome Drug Development Summit 2016, June 28-30, Boston, MA, USA
On June 29, Dr. Bélichard will participate in a panel entitled Pioneer's Panel: Building a Roadmap to Microbiome Drug Development Success at 9:40 am EST.
On June 30, Mr. Clerval will give a presentation entitled Partnering and Research Models of Big Pharma with the Microbiome at 11:00 am EST.
- The Festival of Genomics, June 27-29, Boston, MA, USA
On June 29, Dr. Bélichard will give a presentation entitled To Fix IBD Look at the Microbiome at 2:30 pm EST and will participate in a panel entitled Translating Microbiome Research into Breakthrough Solutions that Promote Health at 4:30 pm EST.
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic investors (Nestlé Health Science, Shire & INRA transfer).
Additional information about Enterome is available through its website: http://www.enterome.com
Contact Pierre Belichard, CEO +33 1 75 77 27 87 David Dible / Mark Swallow / Marine Perrier, Citigate Dewe Rogerson +44 207 638 9571 firstname.lastname@example.org
SOURCE ENTEROME Bioscience